Skip to main content

Table 3 Toxicity for patients treated with pemetrexed plus platinum (n = 53).

From: Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients

Adverse event

Any grade ≥ 1

Grade 1

Grade 2

Grade 3

Grade 4

Leucopenia

26 (49.1)

10 (18.9)

11 (20.8)

3 (5.7)

2 (3.8)

Neutropenia

20 (37.7)

6 (11.3)

9 (17.0)

3 (5.7)

2(3.8)

Thrombocytopenia

17 (32.1)

11 (20.8)

2 (3.8)

2 (3.8)

2 (3.8)

Anemia

8 (15.1)

4 (7.5)

4 (7.5)

-

-

ALT/AST

3 (5.7)

3 (5.7)

-

-

-

Nausea/Vomiting

26 (49.1)

16 (30.2)

9 (17.0)

1 (1.9)

-

Diarrhea

1 (1.9)

-

-

-

1 (1.9)

Creatinine

1 (1.9)

-

-

-

1 (1.9)

Pyrexia

5 (9.4)

4 (7.5)

1 (1.9)

-

-

Fatigue

10 (18.9)

10 (18.9)

-

-

-

Rash

5 (9.4)

1 (1.9)

3 (5.7)

1 (1.9)

-

Inflammation

3 (5.7)

-

3 (5.7)

-

-

  1. Data are number of patients with rates in brackets